Induced protein degradation for therapeutics: past, present, and future
Journal of Clinical Investigation · 02.01.2024 · 134 (1)
DOI: 10.1172/jci175265 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.01.2024. Verfasst von Hojong Yoon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Thalidomide, Multiple Myeloma. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
The concept of induced protein degradation by small molecules has emerged as a promising therapeutic strategy that is particularly effective in targeting proteins previously considered "undruggable." Thalidomide analogs, employed in the treatment of multiple myeloma, stand as prime examples. These compounds serve as molecular glues, redirecting the CRBN E3 ubiquitin ligase to degrade myeloma-dependency factors, IKZF1 and IKZF3. The clinical success of thalidomide analogs demonstrates the therapeutic potential of induced protein degradation. Beyond molecular glue degraders, several additional modalities to trigger protein degradation have been developed and are currently under clinical evaluation. These include heterobifunctional degraders, polymerization-induced degradation, ligand-dependent degradation of nuclear hormone receptors, disruption of protein interactions, and various other strategies. In this Review, we will provide a concise overview of various degradation modalities, their clinical applications, and potential future directions in the field of protein degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Howard Hughes Medical Institute, Boston, Massachusetts, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Yoon, H., Rutter, J. C., Li, Y. D., & Ebert, B. L. (2024). Induced protein degradation for therapeutics: past, present, and future. Journal of Clinical Investigation, 134(1). https://doi.org/10.1172/jci175265
Vancouver
Yoon H, Rutter JC, Li YD, Ebert BL. Induced protein degradation for therapeutics: past, present, and future. Journal of Clinical Investigation. 2024;134(1). doi:10.1172/jci175265
BibTeX
@article{Yoon2024,
author = {Yoon, Hojong and Rutter, Justine C and Li, Yen-Der and Ebert, Benjamin L},
title = {Induced protein degradation for therapeutics: past, present, and future},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {1},
doi = {10.1172/jci175265}
}
EUVIMED